Notice Number: NOT-AR-20-017
Key Dates
Release Date: March 16, 2020
Issued by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Purpose
This notice is to inform SBIR/STTR applicants that NIAMS is participating, effective immediately, PAR-19-333: SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed.
The following sections of PAR-19-333 have been updated to reflect the participation of N?I?A?M?S? in this Notice:
Part 1. Overview Information
Components of Participating Organizations
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Catalog of Federal Domestic Assistance (CFDA) Numbers
93.846
Part 2. Section VII. Agency Contacts
Scientific/Research Contact(s)
Xibin Wang, Ph.D
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-451-3884
Email: [email protected]
Ms. Yen Thach
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-594-3505
Email: [email protected]
With regard to PAR-19-333, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in CRP applications from NIAMS Phase II funded applicants, provided they are within the NIAMS mission. However, NIAMS will not accept applications that include clinical trials. Applicants who wish to submit clinical trial applications to the NIAMS are encouraged to utilize one of the NIAMS clinical trial funding opportunities, which can be found on the NIAMS webpage: http://www.niams.nih.gov/Funding/Clinical_Research/clinical_main.asp.
Budgets may not exceed $400,000 total funding support in any year.
Inquiries
Please direct all inquiries to:
Xibin Wang, Ph.D
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-451-3884
Email: [email protected]
Ms. Yen Thach
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-594-3505
Email: [email protected]